Codexis (CDXS) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Stifel on Codexis, Inc. (CDXS): 'Key Milestones On the Horizon in 2H25'
August 14, 2025 10:35 AM EDTStifel analyst Daniel Arias reiterated a Buy rating and $5.00 price target on Codexis, Inc. (NASDAQ: CDXS).
The analyst comments "CDXS beat consensus on revs and provided a briefing on the encouraging status of the Pharma Biocatalysis business and the ECO Synthesis... More
